Article
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.
Microbial pathogenesis - 1 Jan 2022
Ibrahim Marwa K, AbdElrahman Mohamed, Bader El Din Noha G, Tawfik Salwa, Abd-Elsalam Sherief, Omran Dalia, Barakat Amal Z, Farouk Sally, Elbatae Hassan, El Awady Mostafa K
Abstract excerpt
Hepatitis C virus (HCV) is the leading cause of liver diseases worldwide. At present, combinations of different classes of direct-acting antiviral agents (DAAs) are used as treatment options for HCV, in which sofosbuvir (SOF) is the common DAA among different therapeutic regimes. In Egypt, SOF plus daclatasvir (DCV) is the widely used anti-HCV treatment protocol. Herein, we aimed to assess the association between...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.